Corporate
Responsibility

ESG at Mirum

At Mirum, we are committed to putting the needs of the patient first. This commitment guides our efforts to develop and deliver safe, effective and impactful therapies for patients living with rare diseases. Strong governance structures are crucial to fulfill this mission and deliver value for our stakeholders and we have integrated environmental, social, and governance (ESG) principles and practices across our business to ensure continued transparency and accountability.

In formalizing our approach to ESG at Mirum, we identified and prioritized the ESG topics most relevant to our business and engaged a cross-functional group of experts to guide our efforts. We were also guided by peer benchmarking, stakeholder feedback, and industry best-practices, including the Sustainability Accounting Standards Board (SASB) standard for the Biotechnology and Pharmaceuticals industry.

Our Board of Directors is deeply engaged and involved in overseeing our long-term strategy, including our ESG initiatives. In 2024, we assigned oversight responsibility for ESG matters to our Nominating and Corporate Governance Committee. We continued to make progress on our ESG efforts in 2025, including completing an assessment of climate-related risks and opportunities with potential relevance to our business strategy and financial performance.

For more information on our governance practices, please refer to our proxy statement as well as our Board committee charters:

Addressing Rare Diseases

Mirum is a leading rare disease company with a global footprint of approved products and a broad pipeline of investigational medicines. Purpose-built to bring forward breakthrough medicines for people with overlooked conditions, Mirum focuses on rare liver and rare genetic diseases, where it has built deep expertise and strong connections to patient communities. Because developing and delivering treatments for rare diseases demands urgency and sustained commitment, Mirum focuses on conditions where the burden is profound and the need is greatest, working alongside patients and families who inspire our purpose. From development through delivery, we combine deep expertise with disciplined execution to advance meaningful medicines for people around the world.

Commercial Portfolio 

Mirum’s commercial portfolio includes LIVMARLI® (maralixibat) for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), CHOLBAM® (cholic acid) for bile-acid synthesis disorders, and CTEXLI® (chenodiol) for cerebrotendinous xanthomatosis (CTX).

Please visit the specific product sites for important safety information and labeling considerations that relate to each product.

Patient Assistance

The Mirum Access Plus (MAP) program helps patients and families access support for Mirum medicines, including LIVMARLI, CHOLBAM, and CTEXLI. MAP experts are available to help patients understand the treatment access process, coordinate with healthcare teams, provide information about insurance coverage and potential financial support options, and offer education and resources to help patients start and stay on therapy. Mirum is committed to supporting access to its approved medicines for appropriate patients. LIVMARLI, CHOLBAM, and CTEXLI each have reimbursable pathways with most payers.

At this time, non-commercial access to LIVMARLI and Mirum’s investigational therapies is prioritized through our clinical trials. Where available, compassionate use may be considered in accordance with applicable laws, regulations, and program-specific criteria. Mirum’s Expanded Access Program (EAP) offers access to LIVMARLI for eligible patients with ALGS and PFIC. 

Clinical-Stage Pipeline

Mirum’s clinical-stage pipeline includes volixibat, an IBAT inhibitor in late-stage development for primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC), brelovitug, a fully human monoclonal antibody in late-stage development for chronic hepatitis delta virus (HDV), zilurgisertib, an ALK2 inhibitor under regulatory review with the FDA for fibrodysplasia ossificans progressiva (FOP), and MRM-3379, a PDE4D inhibitor being evaluated for Fragile X syndrome (FXS).

Hands in image

People

At Mirum, we provide our employees with the opportunity to develop and deliver medicines that can potentially change and save lives for our patient communities. This mission transforms our work into more than just a job. We strive to nurture a work environment where our purpose and values can be shared and where people have a voice, create and collaborate, and have meaningful personal and professional experiences. Our employees are inspired every day to go to incredible lengths to make a positive difference for people living with rare diseases.


Talent Attraction and Retention

From early-stage research and clinical trial management to commercialization, our employees’ expertise covers a wide range of disciplines within rare disease and pharmaceutical drug development. Our approach to hiring talent at Mirum is one that is strategic, inclusive, and tailored to the needs of our organization. To attract, retain, and develop talent, we have implemented practices that promote a diverse work culture.

We simplified the recruiting process to minimize barriers and developed a screening process to assess candidates’ skills and cultural fit. During the interview process, we showcase initiatives and programs that emphasize a diverse and inclusive environment, and we highlight opportunities for career growth and professional development. We utilize multiple sources to recruit talent globally, including online job boards, social media, and websites, and have established a large employee referral network as well as professional networking platforms.

Mirum has consistently experienced lower turnover rates compared to the industry average across all levels, including executives and senior managers, mid-level managers, and professionals.

Compensation and Benefits

We care about our employees’ physical and financial wellness and value work-life balance. We offer a competitive salary and benefits package and consider flexible work arrangements.

Our general benefits package includes:

  • Paid Parental Leave
  • Medical, Dental, and Vision Insurance with 100% Company Paid Premium for employees
  • Basic Life Insurance & AD&D
  • Short-Term & Long-Term Disability Insurance
  • 401(k) Retirement Plan with 4% employer match
  • Pre-Tax Commuter Benefits
  • Employee Assistance Program (EAP)
  • Supplemental Health Insurance
  • 11 Paid Company Holidays, as well as a 5-Day shutdown during December
  • 4 Weeks of Accrued Vacation Time per Year

We also provide additional offerings focused on career development and financial wellness, including:

  • Mirum Employee Stock Purchase Plan (ESPP): Employees are eligible to purchase Mirum stock at a discount
  • Tuition Reimbursement for certain continuing education, programs, and/or in an area related to their current position and/or career development
  • Mobile Phone and Internet Reimbursement

Employee Engagement

We seek to make all of our employees feel welcomed and valued. 

2025 Global Engagement Survey

Our most recent employee engagement survey revealed three strengths that showcase the positive sentiment among our workforce:

  • Purposeful Work: 96% of employees are proud to work for Mirum. Employees emphasized the meaningfulness of their work, noting that they strongly believe in our organization's purpose and its impact on improving the lives of patients. This underscores a shared commitment to our mission, contributing to a sense of fulfillment among our team.
  • Warm Onboarding Experience: 93% of employees felt welcomed when they joined our organization. This positive onboarding experience sets the tone for their tenure, fostering a sense of belonging and laying the groundwork for long-term engagement.

     

  • Impactful Contributions: 97% of employees expressed they knew how their work contributes to the goals at Mirum.  This indicates a strong connection between individual roles and the broader mission of our organization, reinforcing a sense of purpose and accomplishment among our employees.

>90% would recommend Mirum as a great place to work, are proud to work here, and felt welcome when they joined. 

We are proud of these strengths and remain committed to further enhancements through continuously listening to and addressing the needs and feedback of our valued employees.

Career Development and Training

At Mirum, we are dedicated to enabling continuous professional development and supporting career advancement for our employees.

Our offerings include:

  • Tailored Manager Workshops: In-person and virtual sessions covering leadership skills, effective communication, and team management.

  • HR Coaching: The HR department offers individual coaching sessions on a case-by-case basis. This personalized approach ensures that employees receive guidance and support tailored to their unique career goals and challenges.

  • Internal Hiring and Lateral Transfers: We actively focus on internal hiring and facilitate lateral transfers to enable employees to explore new roles and learn additional skills. This approach not only supports career advancement but also contributes to the overall growth and diversification of our workforce.

  • Leadership Commitments: Our leadership team has crafted these commitments based on employee feedback, our core values, competencies, and valuable input from our managers. These commitments—Trust Builders, Action Heroes, Feedback Fuel, Lead with Heart and Team Unity —are designed to strengthen our culture and guide our growth.

  • Professional Development: Mirum supports employee development through a tuition reimbursement program, offering up to $5,000 annually (in local currency) for eligible continuing education, certification programs, and job-related courses. This initiative is designed to help employees enhance their skills, advance their careers, and grow within the organization.

  • Direct Feedback Framework (“Go Direct”): Mirum equips employees and managers with the tools and confidence to engage in clear, respectful, and transparent feedback exchanges. This framework strengthens manager–employee relationships, promotes trust and open dialogue, and supports consistent communication across teams, enabling individuals to feel heard, aligned, and empowered to grow.

These offerings are part of our commitment to creating a dynamic and supportive work environment, where employees can continuously develop their skills, pursue career growth opportunities, and achieve their professional aspirations.


Diversity and Inclusion

We strive toward having a diverse team of employees and are committed to diversity, equity, and inclusion (DEI) in the workplace. As part of this commitment, we have established a Culture Team that includes employees across a representative cross-section of departments in both the U.S. and our international offices. Our Culture Team engages in continual discussions across the various business functions to identify potential actions to address areas of improvement and is focused on building accountability across the organization to ensure we meet our diversity objectives.

In our most recent engagement survey, employees highlighted Mirum’s ongoing commitment to fostering a diverse, equitable, and inclusive workplace. Many employees recognized efforts such as inclusive hiring practices, the celebration of diverse cultural events, and an environment that encourages open dialogue and values a wide range of perspectives across teams and levels. At the same time, employees also identified opportunities to further strengthen diversity of thought and representation, particularly across leadership and broader employee groups. These insights reinforce our commitment to continuous improvement. In addition, we regularly evaluate our compensation practices with an external firm to promote pay equity across our workforce. We remain focused on evolving our DEI initiatives to better meet the needs and expectations of our diverse and growing workforce.

Mirum’s 2025 EEO-1 Employee Diversity Statistics

358 full-time global employees as of December 31, 2025

Gender

2025 Executives/ Senior Managers Mid-Level Managers Professionals Grand Total
Female 52% 63% 69% 61%
Male 48% 37% 31% 39%
Grand Total 100% 100% 100% 100%


Ethnicity*

2025 Executives/ Senior Managers Mid-Level Managers Professionals Grand Total
All other ethnicities 0% 0% 3% 1%
Asian 29% 30% 48% 34%
Black or African American 3% 6% 8% 5%
Hispanic or Latino 3% 5% 20% 8%
White 63% 52% 22% 48%
Two or More Races 3% 7% 0% 4%
Grand Total 100% 100% 100% 100%

*Statistics are reported only for U.S. and Canadian employees. EU employees were excluded from the analysis, and 4% of U.S. employees chose not to disclose their ethnicity.

Community Engagement

We actively engage with the communities in which we operate. Our employees participate in hands-on volunteering events, such as Earth Day beach-clean ups and Little Free Library build events. These initiatives not only contribute to a positive company culture but also emphasize our commitment to social responsibility and community involvement.

Anti-Harassment Policy

We strictly prohibit unlawful discrimination and harassment in all its forms and strive to maintain a safe, respectful work environment for all our employees. We conduct comprehensive sexual harassment prevention training for all our U.S. employees, ensuring full compliance with local legislation.

Product Quality and Safety

The quality of our medicinal products is our highest priority. We are committed to meeting all relevant quality standards as we pursue the development of novel therapeutic strategies. It is the responsibility of all Mirum employees and relevant third parties to comply with our quality requirements while maintaining the highest ethical standards in an atmosphere of continuous improvement and innovation.

We do not own or operate manufacturing facilities to produce our approved medicines or any product candidates. We currently depend on third-party contract organizations to manage the manufacturing, testing, packaging, and distribution of our products. We also outsource clinical trial management activities to clinical research organizations (CROs). Utilizing third-party vendors allows us to source high quality expert providers for the unique need each product and study has.

Mirum selects

Our reliance on third parties does not relieve us of our regulatory responsibilities and we are ultimately responsible for compliance with applicable legal and regulatory requirements such as current Good Manufacturing Practices (cGMP), Good Clinical Practices (GCP), Good Laboratory Practices (GLP), Good Documentation Practices (GDP), and Good Pharmacovigilance Practices (GVP).

As part of our Quality Management System (QMS), we have implemented a robust vendor qualification and management program to assess and qualify contracted organizations. This program includes the following processes and activities:

  • Quality oversight of vendor compliance with applicable regulatory requirements, including QMS evaluations through audits and other assessment tools
  • Competency assessments to verify that vendors can carry out the activity or provide purchased materials
  • Change management procedures to review and approve vendor changes before they are enacted
  • Continuous monitoring of the performance of vendors, contract organizations, and the quality of purchased materials
  • Batch record reviews for product disposition

To date, we have not experienced any product recalls or enforcement actions in violation of cGMP. We also have not had any inspections that have resulted in entity voluntary remediation or regulatory or administrative actions taken against Mirum or its CROs.

Supply Chain Management

We are committed to ensuring that our supply chain reflects Mirum’s values and respect for human rights and the environment. Our relationships with suppliers are based on lawful, efficient, and fair practices and we require suppliers by contract to comply with all applicable laws and regulations. We have also implemented a Supplier Code of Conduct to communicate our expectations regarding ethics, labor, and quality to suppliers. For more information, please refer to our California Transparency in Supply Chains Act Disclosure statement.

We maintain traceability of all products in our supply chain and have instituted technologies to our container closure systems to prevent counterfeiting. We also apply serial numbers to enable product traceability at the carton level.

Critical Materials

As our approved medicines are intended to treat rare diseases, we only require a low-volume of raw materials and APIs from suppliers and manufacturers, who in some cases are single-sources for these materials. We select our suppliers based on criteria such as country risk, material risk, supplier risk, and their strategic importance to the business. We maintain long-term supply agreements with our commercial manufacturers, and we maintain sufficient stocks of our drug substances and drug products to ensure business continuity in the event of a production disruption.

Buildings

Data Security and Privacy

As part of our overall risk management processes, we have implemented various information technology (IT) safeguards to protect and secure our networks and data. The Audit Committee of our Board of Directors is responsible for overseeing cybersecurity-related risks, while the Vice President of IT and Information Security is responsible for managing our cybersecurity program and providing reports to the committee about significant cybersecurity threats.

The IT team has put in place incident management protocols to mitigate any potential security breaches, such as multi-factor authentication and disaster recovery software. Moreover, we conduct quarterly cybersecurity training for all our employees, including ongoing, random phishing simulation tests and interactive training sessions. We also maintain a cybersecurity risk insurance policy to protect against potential losses from cybersecurity incidents. To date and to our knowledge, we have not identified any cybersecurity incidents or data breaches.

We take a number of organizational, technical, and physical measures to protect protected health information (PHI) and personally identifiable information (PII). We have established policies and procedures to manage PHI as required by the HIPAA and HITECH Acts. For example, our data governance policy is designed to train relevant employees how to properly manage PHI and PII, and use the principle of least privilege to determine whether employees are allowed access to personal information. For more information, please refer to our Privacy Policy.

Environmental Sustainability

Mirum is committed to ensuring that we operate responsibly with respect to the environment. 

In 2025, we conducted our first greenhouse gas (GHG) emissions assessment, evaluating Scope 1 and Scope 2 emissions across our global operations. This foundational effort establishes a baseline for understanding our carbon footprint and potential reduction efforts.

Our Scope 1 and Scope 2 GHG emissions are shown in the following chart.

Sustainability cover

Scope 1: Direct release of greenhouse gases from sources owned or controlled by Mirum.
Scope 2: Emissions from the generation of electricity, steam, heat, or cooling purchased by Mirum.


We conduct our corporate operations out of our headquarters in Foster City, which is a LEED Gold certified leased facility. Our facilities have several energy-efficiency features, including LED and motion-activated lights as well as EV charging stations. We also aim to minimize our water usage by using low-running faucets, leak detectors, and auto-shut-off valves.

Waste

We are committed to responsible waste management and strive to recycle a majority of the waste generated at our facilities. We do not produce any hazardous or medical waste on site. 

Product Takeback

We participate in a drug take-back program that provides us with DEA-compliant prescription drug take-back receptacles that patients can use to simply and safely dispose of surplus and expired medications. Our patients are currently covered in Washington, Maine, New York, Illinois, California, and Oregon through this program.